VEGF(165) mediates glomerular endothelial repair.

Area of Science:

• Nephrology
• Molecular Biology
• Vascular Biology

Background:

• Vascular Endothelial Growth Factor (VEGF)(165) is a key angiogenic cytokine regulating vascular permeability.
• Its specific role within the renal glomerulus, where it is expressed in visceral epithelial and mesangial cells, remained largely unknown.
• Understanding VEGF(165) function is critical for elucidating glomerular disease pathogenesis.

Purpose of the Study:

• To investigate the role of VEGF(165) in the pathogenesis of glomerular diseases.
• To assess the therapeutic potential of antagonizing VEGF(165) in experimental nephritis models.

Main Methods:

• Administration of a novel, nuclease-resistant RNA aptamer antagonist targeting VEGF(165) to rats.
• Utilized models of normal rats, mesangioproliferative nephritis, passive Heymann nephritis (PHN), and puromycin aminonucleoside nephrosis (PAN).
• Evaluated glomerular pathology, proteinuria, endothelial cell regeneration, and cell death.

Main Results:

• VEGF(165) antagonism did not induce pathology in normal rats.
• In mesangioproliferative nephritis, VEGF(165) blockade reduced endothelial regeneration and increased cell death, leading to microaneurysms.
• VEGF(165) aptamer did not affect disease course in PHN or PAN models.

Conclusions:

• VEGF(165) is essential for glomerular endothelial cell survival and repair in certain kidney diseases.
• Targeting VEGF(165) may offer a novel therapeutic strategy for glomerular diseases involving endothelial cell damage, including glomerulonephritis and thrombotic microangiopathies.
• Further research is warranted to explore VEGF(165) antagonism in specific nephropathies.